HealthAurobindo's Acrotech Biopharma launches atopic dermatitis ointment in US
Acrotech Biopharma, a subsidiary of Aurobindo Pharma, has launched Adquey (difamilast 1%) ointment, a non-steroidal topical treatment for mild-to-moderate atopic dermatitis, in the US. The product, developed by Otsuka Pharmaceutical and licensed to Acrotech, enters a $1.3 billion market. Acrotech also established a dedicated dermatology unit to support its US market ambitions.
Hindu Business··Hyderabad


